Stryker Corp. (NYSE:SYK) has been given a consensus rating of “Buy” by the twenty-three research firms that are currently covering the stock. One investment analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $122.55.

SYK has been the subject of several recent analyst reports. Zacks Investment Research lowered shares of Stryker Corp. from a “buy” rating to a “hold” rating in a research note on Monday, November 14th. SunTrust Banks Inc. initiated coverage on shares of Stryker Corp. in a research note on Thursday, October 13th. They set a “buy” rating and a $140.00 price objective for the company. BMO Capital Markets raised shares of Stryker Corp. from an “underperform” rating to a “market perform” rating and set a $125.00 price objective for the company in a research note on Tuesday, November 1st. They noted that the move was a valuation call. Oppenheimer Holdings Inc. set a $122.00 price objective on shares of Stryker Corp. and gave the stock a “hold” rating in a research note on Sunday, October 30th. Finally, Canaccord Genuity set a $127.00 price objective on shares of Stryker Corp. and gave the stock a “buy” rating in a research note on Sunday, October 30th.

Stryker Corp. (NYSE:SYK) traded up 2.64% during midday trading on Tuesday, reaching $115.93. 1,177,813 shares of the company were exchanged. The company has a 50-day moving average of $113.51 and a 200 day moving average of $115.06. Stryker Corp. has a 52 week low of $86.68 and a 52 week high of $123.55. The firm has a market capitalization of $43.41 billion, a PE ratio of 26.38 and a beta of 0.86.

Stryker Corp. (NYSE:SYK) last posted its earnings results on Thursday, October 27th. The medical technology company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.02. Stryker Corp. had a net margin of 15.24% and a return on equity of 23.61%. The firm earned $2.83 billion during the quarter, compared to analyst estimates of $2.81 billion. During the same period last year, the firm posted $1.25 earnings per share. Stryker Corp.’s revenue for the quarter was up 17.1% compared to the same quarter last year. Equities analysts predict that Stryker Corp. will post $5.78 earnings per share for the current year.

In other news, Director Ronda E. Stryker sold 18,000 shares of the company’s stock in a transaction that occurred on Monday, September 26th. The stock was sold at an average price of $117.56, for a total transaction of $2,116,080.00. Following the completion of the transaction, the director now directly owns 193,142 shares of the company’s stock, valued at approximately $22,705,773.52. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Chairman Kevin Lobo sold 26,306 shares of the company’s stock in a transaction that occurred on Thursday, November 3rd. The stock was sold at an average price of $115.74, for a total value of $3,044,656.44. The disclosure for this sale can be found here. Insiders own 7.80% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in SYK. Blue Chip Partners Inc. increased its position in Stryker Corp. by 0.3% in the second quarter. Blue Chip Partners Inc. now owns 1,757 shares of the medical technology company’s stock valued at $211,000 after buying an additional 6 shares in the last quarter. Washington Trust Bank increased its position in Stryker Corp. by 0.5% in the second quarter. Washington Trust Bank now owns 3,040 shares of the medical technology company’s stock valued at $364,000 after buying an additional 15 shares in the last quarter. Wetherby Asset Management Inc. increased its position in Stryker Corp. by 0.3% in the second quarter. Wetherby Asset Management Inc. now owns 6,242 shares of the medical technology company’s stock valued at $748,000 after buying an additional 18 shares in the last quarter. Douglas Lane & Associates LLC increased its position in Stryker Corp. by 0.7% in the second quarter. Douglas Lane & Associates LLC now owns 2,945 shares of the medical technology company’s stock valued at $353,000 after buying an additional 20 shares in the last quarter. Finally, Wade G W & Inc. increased its position in Stryker Corp. by 1.0% in the third quarter. Wade G W & Inc. now owns 2,230 shares of the medical technology company’s stock valued at $260,000 after buying an additional 22 shares in the last quarter. 74.90% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Stryker Corp. (SYK) Given Consensus Recommendation of “Buy” by Analysts” was published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/29/stryker-corp-syk-given-consensus-recommendation-of-buy-by-analysts.html.

About Stryker Corp.

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

5 Day Chart for NYSE:SYK

Receive News & Stock Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related stocks with our FREE daily email newsletter.